<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04390984</url>
  </required_header>
  <id_info>
    <org_study_id>HR-APTN-DDI-004</org_study_id>
    <nct_id>NCT04390984</nct_id>
  </id_info>
  <brief_title>Drug-drug Interaction Study of Gefitinb on Apatinib in NSCLC Patients</brief_title>
  <official_title>A Multi-center, Open-label, Fixed-sequence Study of Effect of Gefitinib on the Pharmacokinetics of Apatinib Mesylate in Non-squamous, Non-small-cell Lung Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu HengRui Medicine Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu HengRui Medicine Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study was to assess the effect of gefitinib on the
      pharmacokinetics of apatinib mesylate in lung cancer patients.

      The secondary objective of the study was to assess the pharmacokinetics of gefitinib, and to
      assess the safety of apatinib mesylate and gefitinib administered in lung cancer patients.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2020</start_date>
  <completion_date type="Anticipated">August 2020</completion_date>
  <primary_completion_date type="Anticipated">July 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>All the subjects will administrated with apatinib and gefitinib following the same sequence to assess the effect of gefitinib on the pharmacokinetics of apatinib in NSCLC patients</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>0-24 hours</time_frame>
    <description>Maximum Observed Plasma Concentration for apatinib</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-τ</measure>
    <time_frame>0-24 hours</time_frame>
    <description>Area Under the Concentration-time Curve From Zero (Pre-dose) to 24 hours</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>NSCLC</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will be administrated with 500mg apatinib on day 1 and day 12-15, and administrated with gefitinib on day 4-15.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib Mesylate, Gefitinib</intervention_name>
    <description>Subjects will be administrated with 500mg apatinib on day 1 and day 12-15, and administrated with gefitinib on day 4-15.</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1) 18-75 years of age. 2) ECOG performance status: level 0~1; 3) Anticipated life
             expectancy ≥ 12 weeks; 4) Lung cancer patients; 5) Major organs in good function; 6)
             Agree to take approved method of contraception during the clinical trail and 8 weeks
             after the last dose of apatinib. Female subject should be negative in the pregnancy
             test; 7) Able to comprehend and willing to sign an informed consent form (ICF)

        Exclusion Criteria:

          1. History of drug allergy, or allergic to apatinib or gefitinib or ingredients;

          2. Squamous cancer, small-cell lung cancer;

          3. Brain metastases;

          4. Hypertension and couldn't be controlled with medicine;

          5. Coagulation disorders;

          6. Clinical significant bleeding in 3 months prior dosing;

          7. Had surgery in four weeks prior dosing;

          8. Disease that affect drug absorption, such as inability to swallow, chronic diarrhea
             and intestinal obstruction;

          9. Abdominal fistula, gastrointestinal perforation or intraperitoneal abscess in 6 months
             prior dosing;

         10. Urine protein ≥++, and urine protein ≥1.0g in 24 hours;

         11. Active infection and need antimicrobial treatments;

         12. History of psychiatric substance abuse;

         13. Take any clinical trial drugs within four weeks prior dosing;

         14. Take any drugs that have effect on gastric acid and metabolic enzyme CYP 3A and
             CYP2D6;

         15. Combined with other viral infections (anti-HCV, anti-HIV positive, HBsAg positive) or
             combined with syphilis infection;

         16. Addicted to alcohol and tobacco;

         17. Take grapefruit or grapefruit product, drinks containing caffeine, xanthine and
             alcohol in 48 hours prior dosing;

         18. The investigator believes that the subjects are not eligible to participate in this
             trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yuya Wang, Ph.D</last_name>
    <phone>13918749176</phone>
    <email>wangyuya@hrglobe.cn</email>
  </overall_contact>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 13, 2020</study_first_submitted>
  <study_first_submitted_qc>May 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 18, 2020</study_first_posted>
  <last_update_submitted>May 15, 2020</last_update_submitted>
  <last_update_submitted_qc>May 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apatinib</mesh_term>
    <mesh_term>Gefitinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

